BIIB

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Biogen to present new nephrology data, including long-term Phase 3 EMPAVELI (pegcetacoplan) results, at ASN Kidney WeekOct 19, 2026
• Biogen's lupus program gains momentum as 52-week data show durable skin improvements with litifilimabOct 5, 2026
• Biogen's litifilimab shows rapid and durable efficacy in new 52-week Phase 2 data from the ongoing Phase 2/3 AMETHYST study, supporting its potential as a first-in-class therapy for cutaneous lupus erythematosusOct 4, 2026
• Phase 3 pediatric EMPAVELI data published in CJASN showed reduced proteinuria and stabilized kidney function in adolescents with C3G or primary IC-MPGNSep 18, 2026
• Japan approved the LEQEMBI Pen, a subcutaneous formulation of LEQEMBI, for early Alzheimer’s diseaseSep 16, 2026